Matches in SemOpenAlex for { <https://semopenalex.org/work/W2585114217> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2585114217 abstract "Abstract Backgroud: Although the introduction of rituximab as a first-line treatment has improved outcome of post-transplant lymphoproliferative disorder (PTLD), PTLD with central nervous system involvement (CNS-PTLD) still has a dismal prognosis because of low penetrance across the blood-brain barrier. In this prospective study, we reported intrathecal rituximab was efficacy and safety in the patients with CNS-PTLD who had failed to respond to the intravenous rituximab-based treatments. Methods: From June 2009 to November 2013, 32 cases of EBV-associated PTLD were recorded in the Southern Medical University Institute of Hematology. Fourteen patients diagnosed with CNS-PTLD were enrolled in this prospective study. For the patients who failed to response to the initial intravenous rituximab-based treatments, sequential dose-escalation schedule of intrathecal rituximab (initial dose of 20mg, increased by 10mg each week and maximum dose of 50 mg) was administrated weekly. Results: Three patients were responsive and 11 were unresponsive to the initial treatments within one week after the treatments. For the 11 patients who failed to respond to the initial treatments, 9 patients received intrathecal rituximab within 7-11 days and 2 patients refused the treatment. After two cycles of rituximab-based treatments, 10 patients achieved complete response (CR), 2 patients were partial response and 2 patients were non-response. With a median follow up of 664 (range 18 to 1545) days after the diagnosis of CNS-PTLD, 7 patients survived and 7 died. The causes of death included PTLD progressing (n=3), PTLD relapse (n=1), GVHD (n=1), CMV pneumonia (n=1) and pseudomonas aeruginosa sepsis (n=1). The 3-year probability of OS was 45.7% ±14.7% in CNS-PTLD, which was no significant difference as compared to PTLD without CNS involvement(55.6% ±11.7%, P=0.706). Conclusion: Intrathecal rituximab might be an effective and safe method for CNS-PTLD in the allo-HSCT recipients who were unresponsive to the intravenous rituximab-based treatments. Disclosures No relevant conflicts of interest to declare." @default.
- W2585114217 created "2017-02-10" @default.
- W2585114217 creator A5000828146 @default.
- W2585114217 creator A5010298865 @default.
- W2585114217 creator A5018722248 @default.
- W2585114217 creator A5029593270 @default.
- W2585114217 creator A5032457247 @default.
- W2585114217 creator A5034407018 @default.
- W2585114217 creator A5036304210 @default.
- W2585114217 creator A5041183580 @default.
- W2585114217 creator A5053447705 @default.
- W2585114217 creator A5071773009 @default.
- W2585114217 creator A5077083856 @default.
- W2585114217 creator A5082138222 @default.
- W2585114217 date "2015-12-03" @default.
- W2585114217 modified "2023-09-26" @default.
- W2585114217 title "Intrathecal Rituximab for EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement Unresponsive to Intravenous Rituximab-Based Treatments: A Prospective Study" @default.
- W2585114217 doi "https://doi.org/10.1182/blood.v126.23.4352.4352" @default.
- W2585114217 hasPublicationYear "2015" @default.
- W2585114217 type Work @default.
- W2585114217 sameAs 2585114217 @default.
- W2585114217 citedByCount "0" @default.
- W2585114217 crossrefType "journal-article" @default.
- W2585114217 hasAuthorship W2585114217A5000828146 @default.
- W2585114217 hasAuthorship W2585114217A5010298865 @default.
- W2585114217 hasAuthorship W2585114217A5018722248 @default.
- W2585114217 hasAuthorship W2585114217A5029593270 @default.
- W2585114217 hasAuthorship W2585114217A5032457247 @default.
- W2585114217 hasAuthorship W2585114217A5034407018 @default.
- W2585114217 hasAuthorship W2585114217A5036304210 @default.
- W2585114217 hasAuthorship W2585114217A5041183580 @default.
- W2585114217 hasAuthorship W2585114217A5053447705 @default.
- W2585114217 hasAuthorship W2585114217A5071773009 @default.
- W2585114217 hasAuthorship W2585114217A5077083856 @default.
- W2585114217 hasAuthorship W2585114217A5082138222 @default.
- W2585114217 hasConcept C126322002 @default.
- W2585114217 hasConcept C141071460 @default.
- W2585114217 hasConcept C188816634 @default.
- W2585114217 hasConcept C194409129 @default.
- W2585114217 hasConcept C2776995267 @default.
- W2585114217 hasConcept C2779338263 @default.
- W2585114217 hasConcept C2780653079 @default.
- W2585114217 hasConcept C2781146716 @default.
- W2585114217 hasConcept C71924100 @default.
- W2585114217 hasConcept C90924648 @default.
- W2585114217 hasConceptScore W2585114217C126322002 @default.
- W2585114217 hasConceptScore W2585114217C141071460 @default.
- W2585114217 hasConceptScore W2585114217C188816634 @default.
- W2585114217 hasConceptScore W2585114217C194409129 @default.
- W2585114217 hasConceptScore W2585114217C2776995267 @default.
- W2585114217 hasConceptScore W2585114217C2779338263 @default.
- W2585114217 hasConceptScore W2585114217C2780653079 @default.
- W2585114217 hasConceptScore W2585114217C2781146716 @default.
- W2585114217 hasConceptScore W2585114217C71924100 @default.
- W2585114217 hasConceptScore W2585114217C90924648 @default.
- W2585114217 hasLocation W25851142171 @default.
- W2585114217 hasOpenAccess W2585114217 @default.
- W2585114217 hasPrimaryLocation W25851142171 @default.
- W2585114217 hasRelatedWork W1540507981 @default.
- W2585114217 hasRelatedWork W1977777197 @default.
- W2585114217 hasRelatedWork W2122074792 @default.
- W2585114217 hasRelatedWork W2146046645 @default.
- W2585114217 hasRelatedWork W2285970514 @default.
- W2585114217 hasRelatedWork W2507690749 @default.
- W2585114217 hasRelatedWork W2512053872 @default.
- W2585114217 hasRelatedWork W2560495272 @default.
- W2585114217 hasRelatedWork W2561845045 @default.
- W2585114217 hasRelatedWork W2574123108 @default.
- W2585114217 hasRelatedWork W2578876390 @default.
- W2585114217 hasRelatedWork W2591604011 @default.
- W2585114217 hasRelatedWork W2889915033 @default.
- W2585114217 hasRelatedWork W2896562199 @default.
- W2585114217 hasRelatedWork W2980090598 @default.
- W2585114217 hasRelatedWork W2980825308 @default.
- W2585114217 hasRelatedWork W3031362729 @default.
- W2585114217 hasRelatedWork W3161248702 @default.
- W2585114217 hasRelatedWork W936474408 @default.
- W2585114217 hasRelatedWork W2600495222 @default.
- W2585114217 isParatext "false" @default.
- W2585114217 isRetracted "false" @default.
- W2585114217 magId "2585114217" @default.
- W2585114217 workType "article" @default.